Bausch + Lomb/$BLCO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Ticker
$BLCO
Sector
Primary listing
NYSE
Employees
13,500
Headquarters
Vaughan, Canada
Website
Bausch + Lomb Metrics
BasicAdvanced
$5.4B
-
-$0.78
0.63
-
Price and volume
Market cap
$5.4B
Beta
0.63
52-week high
$20.37
52-week low
$10.45
Average daily volume
494K
Financial strength
Current ratio
1.547
Quick ratio
0.736
Long term debt to equity
75.768
Total debt to equity
76.199
Interest coverage (TTM)
0.24%
Profitability
EBITDA (TTM)
530
Gross margin (TTM)
59.68%
Net profit margin (TTM)
-5.58%
Operating margin (TTM)
2.07%
Effective tax rate (TTM)
33.42%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
0.47%
Return on equity (TTM)
-4.02%
Valuation
Price to revenue (TTM)
1.096
Price to book
0.84
Price to tangible book (TTM)
-3.39
Price to free cash flow (TTM)
-32.491
Free cash flow yield (TTM)
-3.08%
Free cash flow per share (TTM)
-0.468
Growth
Revenue change (TTM)
8.81%
Earnings per share change (TTM)
-39.78%
3-year revenue growth (CAGR)
8.97%
3-year earnings per share growth (CAGR)
26.26%
Bulls say / Bears say
The IPO in May 2025 priced 35 million shares at $18, below its $21–$24 target range, reflecting weaker-than-anticipated investor demand and raising concerns about the company’s growth outlook (Reuters).
Board members Brett Icahn and Gary Hu resigned on August 18, 2025, after Carl Icahn’s agreement ended, potentially creating a period of governance uncertainty and strategic distraction (Reuters).
Alcon’s FDA approval of its new dry-eye treatment Tryptyr on May 28, 2025, intensifies competition in the dry-eye market and may pressure sales of Bausch + Lomb’s Xiidra franchise (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Bausch + Lomb News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch + Lomb stock?
Bausch + Lomb (BLCO) has a market cap of $5.4B as of October 29, 2025.
What is the P/E ratio for Bausch + Lomb stock?
The price to earnings (P/E) ratio for Bausch + Lomb (BLCO) stock is 0 as of October 29, 2025.
Does Bausch + Lomb stock pay dividends?
No, Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Bausch + Lomb dividend payment date?
Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch + Lomb?
Bausch + Lomb (BLCO) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.